Accessibility Menu
Alumis logo

Alumis(NASDAQ) ALMS

Market Cap$1.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+64%
5 YearN/A
1 Year+104%
1 Month-66%
Premium Feature
Moneyball Superscore
64/100
$9.49
-56.51%
-12.33Today
Pre market$9.76+$0.27 (+2.85%)
Alumis last closing stock price
MetricPriceDate
Last closeUSD 9.472026-09-01
Alumis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-60.48%USD 23.962026-08-25
1 month-66.48%USD 28.252026-07-31
3 month-52.84%USD 20.082026-06-03
Year to date-2.97%USD 9.762025-12-31
1 year+104.09%USD 4.642025-08-29
Since inception+63.98%USD 13.302024-06-28

Alumis Financials at a Glance

Market Cap

$1.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$7.40M

Net Income (TTM)

-$438.96M

EPS (TTM)

-$3.81

P/E Ratio

-2.49

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$9.49

Volume

63,172.768

Open

$9.93

Previous Close

$9.47

Daily Range

$8.75 - $11.06

52-Week Range

$3.76 - $31.35

Estimated Earnings Date

Nov 12, 2026

ALMS News

f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

Jonathan PoncianoMay 24, 2026
BuyAlert-Green.png

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Jonathan PoncianoMay 17, 2026
SellAlert-Green.png

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Jonathan PoncianoMay 15, 2026
PiggyBank-BuyAlert-Blue.png

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug

Jonathan PoncianoMay 10, 2026
SellAlert-Purple.png

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

Jonathan PoncianoFeb 3, 2026
BuyAlert-Blue.png

An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million

Cory RenauerJan 17, 2026
STOCK-MARKET-DAILY-ONLY-BullBear-Blue-Pink.png

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Howard SmithJan 6, 2026
Foolcom-Featured.png

Alumis Misses Q2 Revenue as Costs Jump

Motley Fool Markets TeamAug 13, 2025

ALMS: Motley Fool Moneyball Superscore

64

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alumis

Alumis Inc. makes medicines for immune system disorders. Its treatments target specific causes of psoriasis and lupus. These drugs aim to improve lives without weakening the whole body.

Fighting Disease From Within

  • Envu: A second-generation drug candidate being tested for plaque psoriasis and lupus; currently in Phase 3 clinical trials.
  • A-005: A brain-penetrating medicine for neurodegenerative diseases; recently completed Phase 1 testing in healthy volunteers.
  • Lonigutamab: An antibody treatment for thyroid eye disease; currently undergoing a strategic review for potential sale or partnership.
  • TYK2 Platform: A research system used to find and develop targeted therapies for autoimmune conditions.

Building a Drug Pipeline

  • Acquired ACELYRIN in May 2025 to expand its drug assets and research programs.
  • Partnered with Kaken Pharmaceutical in March 2025 to develop and sell envu in Japan.
  • Raised $324.4 million in net proceeds through a public stock offering in Jan. 2026.
  • Completed enrollment for two pivotal Phase 3 clinical trials in early 2026.

A Different Path to Healing

The company develops drugs that block specific signals without shutting down the entire immune system. This targeted approach uses advanced chemistry to improve how patients tolerate their medicine.

What the Books Show

  • Net loss was $235.3 million for the six months ended June 30, 2026, up 493% year over year.
  • Total revenue reached $3.4 million for the six months ended June 30, 2026, down 83% year over year.
  • Research and development expenses were $166.9 million for the first half of 2026, down 19% year over year.
  • The company held $502.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
  • Accumulated deficit reached $1,137.2 million at the end of the second quarter of 2026.

The Final Word

Alumis has evolved from an early-stage startup into a company with multiple late-stage drug trials. It maintains its focus on precision medicines through strategic acquisitions and global partnerships.

AI Generated • Aug 14, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

224

CEO

Martin Babler

Website

www.alumis.com

Headquarters

South San Francisco, CA 94080, US

ALMS Financials

Key Financial Metrics (TTM)

Gross Margin

88.23%

Operating Margin

-6204.39%

Net Income Margin

-5933.45%

Return on Equity

-102.97%

Return on Capital

-126.31%

Return on Assets

-78.30%

Earnings Yield

-40.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

133.50M

Volume

63.17K

Avg. Volume

1.71M

Financials (TTM)

Gross Profit

$6.53M

Operating Income

-$459.00M

EBITDA

-$442.87M

Operating Cash Flow

-$351.40M

Capital Expenditure

-$401.00K

Free Cash Flow

-$351.80M

Cash & ST Invst.

$502.29M

Total Debt

$36.43M

Alumis Performance Analysis

Alumis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 24,050,000N/A
Alumis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-22.5%
Q42025-12-31-6.6%
Q12026-03-31-9.7%
Q22026-06-30-4.5%
Alumis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.16N/A
20232023-12-31USD -2.9938.5%
20242024-12-31USD -5.4180.9%
20252025-12-31USD -2.86-47.1%
Alumis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-237.7%
Q42025-12-3116.0%
Q12026-03-3116.9%
Q22026-06-30-50.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.66M

-37.7%

Gross Profit

$1.66M

-37.7%

Gross Margin

100.00%

N/A

Market Cap

$1.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.33M

N/A

Employees

237

N/A

Net Income

-$142.22M

-339.7%

EBITDA

-$148.78M

-24.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$502.29M

+3.3%

Total Debt

$36.43M

-6.1%

Accounts Receivable

$3.86M

-50.9%

Inventory

$0.00

N/A

Long Term Debt

$31.61M

-9.0%

Short Term Debt

$4.82M

+18.8%

Return on Assets

-78.30%

N/A

Return on Invested Capital

-94.76%

N/A

Free Cash Flow

-$81.74M

+23.6%

Operating Cash Flow

-$81.50M

+23.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OMEROmeros Corporation
$18.75-0.21%
LXRXLexicon Pharmaceuticals, Inc.
$2.19-2.67%
RAPTRAPT Therapeutics, Inc.
$58.01+0.00%
ETONEton Pharmaceuticals, Inc.
$60.43-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$52.22+0.07%
IBITiShares Bitcoin Trust
$43.76-0.02%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$105.91-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$69.15-0.04%

Questions About ALMS

What is the current price of Alumis?

Alumis is trading at $9.47 per share.

What is the 52-week range for Alumis?

Over the past 52 weeks, Alumis has traded between $3.76 and $31.35.

How much debt does Alumis have?

As of the most recent reporting period, Alumis reported total debt of $36.43M.

How much cash does Alumis have on hand?

Alumis reported $63.71M in cash and cash equivalents in its most recent financial results.

What is Alumis’s dividend yield?

Alumis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services